Arcutis Biotherapeutics, Inc. vs Pfizer, Inc. — Stock Comparison

ARQT
Arcutis Biotherapeutics, Inc.
$23.35
▲ 0.56%
vs
PFE
Pfizer, Inc.
$26.33
▼ 1.39%
Q·Score Winner
Arcutis Biotherapeutics, Inc.
ARQT7/10vs 6.5/10

Q·Score Breakdown

7
Bullish
Overall
6.5
Neutral
2.6
Quality
7.4
8.2
Health
7
8.3
Growth
5.6
9.1
Valuation
6.7
7.9
Sentiment
5.2
ARQT

Consensus analyst target of $34.75 is 49% above current price.

currently unprofitable (-4% margin).

PFE

Strong profitability with 12% net profit margins.

analyst sentiment is cautious.

Analyst Consensus

BUY
Target $34.75 (+48.8%)
8 analysts
HOLD
Target $29.00 (+10.2%)
27 analysts

Fundamentals

ARQT
PFE
Trailing P/E
19.4×
19.4×
Forward P/E
9.4×
-4.3%
Profit Margin
12.4%
90.2%
Gross Margin
75.8%
-9.3%
ROE
8.9%
81.5%
Revenue Growth
-1.2%
Earnings Growth
1.77
Beta
0.39
Price / Book
$2.9B
Market Cap
$149.8B
$12 – $32
52-Week Range
$22 – $29

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →